Recent studies have demonstrated significant pathologic responses and relapse-free survival in patients with stage-III MM treated with anti-CTLA-4 + anti-PD1 monoclonal antibodies, but ∼20% of patients do not respond to this treatment (Kaptein et al., 2022). This evidence concerns the gene CTLA4 and Miyoshi myopathy.